We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Data Filtering Tool Helps Identify Pathogenic Mutations

By LabMedica International staff writers
Posted on 24 Jan 2016
A new tool designed to assist geneticists to differentiate between pathogenic and harmless mutations is now available on the Internet.

The fraction of the genes that codes for proteins is called the exome, and genome wide analysis has revealed that while the DNA of a patient with a monogenic disease contains about 20,000 variations, only one or two are disease causing. More...
Thus, it is that 58% of rare variants in the protein-coding exome of the general population are located in only 2% of the genes.

To help differentiate between the many harmless variations and the few that are linked to disease, investigators at the Rockefeller Institute (New York, NY, USA) developed the gene damage index (GDI). The GDI is a data analysis tool that weighs how frequently the gene is mutated in the general population and calculates the importance of a given gene in a specific disease group, including Mendelian disorders, cancer, autism, and primary immunodeficiencies.

The investigators compared GDI with the leading gene-level approaches, genic intolerance, and de novo excess, and demonstrated that GDI performed best for the detection of false positives (i.e., removing exome variants in genes irrelevant to disease), whereas genic intolerance and de novo excess performed better for the detection of true positives (i.e., assessing de novo mutations in genes likely to be disease causing).

“To find a needle in the haystack, it helps to get rid of some of the hay,” said first author Dr. Yuval Itan, a researcher in the St. Giles Laboratory of Human Genetics of Infectious Disease at the Rockefeller Institute. “Filtering out the noise, the genes that pollute the data, is crucial. With this method, up to 60% of the irrelevant variants can be removed. The Gene Damage Index will help scientists more easily sort through the large amounts of data produced by next-generation sequencing.”

The GDI study was published in the November 3, 2015, issue of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

Rockefeller Institute



New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Collection and Transport System
PurSafe Plus®
Rapid Molecular Testing Device
FlashDetect Flash10
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.